These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22495733)

  • 1. The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death.
    Westreich D; Cole SR; Young JG; Palella F; Tien PC; Kingsley L; Gange SJ; Hernán MA
    Stat Med; 2012 Aug; 31(18):2000-9. PubMed ID: 22495733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.
    Cole SR; Hernán MA; Robins JM; Anastos K; Chmiel J; Detels R; Ervin C; Feldman J; Greenblatt R; Kingsley L; Lai S; Young M; Cohen M; Muñoz A
    Am J Epidemiol; 2003 Oct; 158(7):687-94. PubMed ID: 14507605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marginal structural models for case-cohort study designs to estimate the association of antiretroviral therapy initiation with incident AIDS or death.
    Cole SR; Hudgens MG; Tien PC; Anastos K; Kingsley L; Chmiel JS; Jacobson LP
    Am J Epidemiol; 2012 Mar; 175(5):381-90. PubMed ID: 22302074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using marginal structural measurement-error models to estimate the long-term effect of antiretroviral therapy on incident AIDS or death.
    Cole SR; Jacobson LP; Tien PC; Kingsley L; Chmiel JS; Anastos K
    Am J Epidemiol; 2010 Jan; 171(1):113-22. PubMed ID: 19934191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Marginal structural models application to estimate the effects of antiretroviral therapy in 5 cohorts of HIV seroconverters].
    Pérez-Hoyos S; Ferreros I; Hernán MA;
    Gac Sanit; 2007; 21(1):76-83. PubMed ID: 17306191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula.
    Young JG; Cain LE; Robins JM; O'Reilly EJ; Hernán MA
    Stat Biosci; 2011 Sep; 3(1):119-143. PubMed ID: 24039638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count.
    Cole SR; Hernán MA; Margolick JB; Cohen MH; Robins JM
    Am J Epidemiol; 2005 Sep; 162(5):471-8. PubMed ID: 16076835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula.
    Edwards JK; Cole SR; Moore RD; Mathews WC; Kitahata M; Eron JJ
    Am J Epidemiol; 2018 Aug; 187(8):1808-1816. PubMed ID: 29420696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study.
    Chammartin F; Lodi S; Logan R; Ryom L; Mocroft A; Kirk O; d'Arminio Monforte A; Reiss P; Phillips A; El-Sadr W; Hatleberg CI; Pradier C; Bonnet F; Law M; De Wit S; Sabin C; Lundgren JD; Bucher HC;
    Ann Intern Med; 2021 Jun; 174(6):768-776. PubMed ID: 33721519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
    Lodi S; Phillips A; Logan R; Olson A; Costagliola D; Abgrall S; van Sighem A; Reiss P; Miró JM; Ferrer E; Justice A; Gandhi N; Bucher HC; Furrer H; Moreno S; Monge S; Touloumi G; Pantazis N; Sterne J; Young JG; Meyer L; Seng R; Dabis F; Vandehende MA; Pérez-Hoyos S; Jarrín I; Jose S; Sabin C; Hernán MA;
    Lancet HIV; 2015 Aug; 2(8):e335-43. PubMed ID: 26423376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death.
    Cain LE; Cole SR
    Stat Med; 2009 May; 28(12):1725-38. PubMed ID: 19347843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An information criterion for marginal structural models.
    Platt RW; Brookhart MA; Cole SR; Westreich D; Schisterman EF
    Stat Med; 2013 Apr; 32(8):1383-93. PubMed ID: 22972662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.
    Wada N; Jacobson LP; Cohen M; French A; Phair J; Muñoz A
    Am J Epidemiol; 2013 Jan; 177(2):116-25. PubMed ID: 23287403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.
    Sterne JA; Hernán MA; Ledergerber B; Tilling K; Weber R; Sendi P; Rickenbach M; Robins JM; Egger M;
    Lancet; 2005 Jul 30-Aug 5; 366(9483):378-84. PubMed ID: 16054937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection.
    Thiébaut R; Jacqmin-Gadda H; Babiker A; Commenges D;
    Stat Med; 2005 Jan; 24(1):65-82. PubMed ID: 15523706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.